<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861717</url>
  </required_header>
  <id_info>
    <org_study_id>KELD-ESS-0413</org_study_id>
    <nct_id>NCT01861717</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.</brief_title>
  <official_title>A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Wayne Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>John Wayne Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      If someone is diagnosed with a pituitary tumor that causes acromegaly (too much growth&#xD;
      hormone) the treatment is to have it surgically removed. This study has two phases.&#xD;
&#xD;
      The first phase provides medical treatment with a drug that will be provided for 3 months&#xD;
      before surgery to see if complications of surgery are reduced and to see whether or not&#xD;
      remission improves following surgery if you have this medical treatment. The drug&#xD;
      administered is approved by the FDA for long-term treatment of acromegaly. It is not&#xD;
      routinely administered before surgery, and is therefore experimental as used in this way. All&#xD;
      other procedures performed during this research are standard of care with the exception of&#xD;
      the 3 questionnaires to be completed at each visit.&#xD;
&#xD;
      The second phase of this study is from 3 months until 12 months after surgery and is only for&#xD;
      people who do not go into remission after the operation. This phase assesses the possible&#xD;
      remission of acromegaly after resuming the drug treatment for an additional 3 to 9 months.&#xD;
      The drug will be prescribed by your physician as part of your regular medical care and will&#xD;
      not be included as part of the study. All other procedures performed during this research are&#xD;
      standard of care with the exception of the 3 questionnaires to be completed at each visit.&#xD;
&#xD;
      The study lasts approximately 16 months - 3 month before surgery and 12 months after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Didn't enroll enough subjects&#xD;
  </why_stopped>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Remission of Acromegaly</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Early remission status after a 12 week course of pre-operative Somatuline Depot and 3 months after endonasal endoscopic surgery. Remission status will be based on age-adjusted Insulin Glucose Factor 1 (IGF-1) levels and oral glucose tolerance test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Function</measure>
    <time_frame>3 month post-op</time_frame>
    <description>Changes in cardiac function after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hypertension</measure>
    <time_frame>3 months</time_frame>
    <description>Change in hypertension after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Respiratory Function</measure>
    <time_frame>12 weeks and 3 months</time_frame>
    <description>Change in respiratory function after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>3 months</time_frame>
    <description>Change in Quality of Life after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Remission Status 1 Year After Surgery</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Remission status one year after surgery and time to achieve remission in patients who did not achieve remission after endonasal endoscopic surgery and who had resumption of Somatuline Depot therapy 3 months after surgery.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Somatuline Depot Subcutaneous (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lanreotide</intervention_name>
    <description>Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
    <arm_group_label>Somatuline Depot Subcutaneous (SC)</arm_group_label>
    <other_name>Somatuline Depot SC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 - 75&#xD;
&#xD;
          -  elevated serum Insulin-like growth factor-1 (IGF-1) level above age- and sex-based&#xD;
             normal values and failure of growth hormone(GH) suppression to &lt; 1.0 ng/ml after a 75&#xD;
             gm oral glucose tolerance test (OGTT) American Association of Clinical Endocrinolgists&#xD;
             (AACE) Acromegaly Clinical Guidelines 2004&#xD;
&#xD;
          -  visible pituitary adenoma (microadenoma or macroadenoma) on high quality pituitary MRI&#xD;
             without and with gadolinium&#xD;
&#xD;
          -  prior treatments for acromegaly with surgery, somatostatin analogs or pegvisomant are&#xD;
             acceptable if these therapies have been discontinued for at least 3 months prior to&#xD;
             study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 or &gt; 75 years&#xD;
&#xD;
          -  acromegalic patients currently on a lanreotide or octreotide preparation or on&#xD;
             pegvisomant&#xD;
&#xD;
          -  patients who have received prior radiotherapy or radiosurgery&#xD;
&#xD;
          -  patients with adenoma-related visual acuity or visual field deficit from optic nerve&#xD;
             and/or chiasm compression or severe optic nerve/chiasm compression in the setting of&#xD;
             normal visual fields and acuity&#xD;
&#xD;
          -  patients with pituitary apoplexy defined as recent tumor hemorrhage and/or infarction&#xD;
             on MRI with associated symptoms of new onset visual loss, diplopia and/or adrenal&#xD;
             insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel F Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Wayne Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain Tumor Center and Pituitary Disorders Program, John Wayne Cancer Institute, Saint John's Health System</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://newstjohns.org/braintumorcenter.aspx</url>
    <description>Brain Tumor Center and Pituitary Disorders Program, John Wayne Cancer Institute at Saint John's Health Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2013</study_first_posted>
  <results_first_submitted>September 2, 2021</results_first_submitted>
  <results_first_submitted_qc>September 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2021</results_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>excess growth hormone</keyword>
  <keyword>excess GH</keyword>
  <keyword>gigantism</keyword>
  <keyword>pituitary tumor</keyword>
  <keyword>pituitary adenoma</keyword>
  <keyword>growth hormone tumor</keyword>
  <keyword>GH secreting adenoma</keyword>
  <keyword>Somatuline</keyword>
  <keyword>lanreotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruited between May 2013 and January 2016, in outpatient cancer center clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Somatuline Depot Subcutaneous (SC)</title>
          <description>Somatuline Depot Subcutaneous (SC) 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Consented to participate in study</population>
      <group_list>
        <group group_id="B1">
          <title>Somatuline Depot SC</title>
          <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Early Remission of Acromegaly</title>
        <description>Early remission status after a 12 week course of pre-operative Somatuline Depot and 3 months after endonasal endoscopic surgery. Remission status will be based on age-adjusted Insulin Glucose Factor 1 (IGF-1) levels and oral glucose tolerance test.</description>
        <time_frame>3 months post-op</time_frame>
        <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Somatuline Depot Subcutaneous (SC)</title>
            <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Early Remission of Acromegaly</title>
          <description>Early remission status after a 12 week course of pre-operative Somatuline Depot and 3 months after endonasal endoscopic surgery. Remission status will be based on age-adjusted Insulin Glucose Factor 1 (IGF-1) levels and oral glucose tolerance test.</description>
          <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cardiac Function</title>
        <description>Changes in cardiac function after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal.</description>
        <time_frame>3 month post-op</time_frame>
        <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Somatuline Depot SC</title>
            <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Function</title>
          <description>Changes in cardiac function after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal.</description>
          <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hypertension</title>
        <description>Change in hypertension after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
        <time_frame>3 months</time_frame>
        <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Somatuline Depot SC</title>
            <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypertension</title>
          <description>Change in hypertension after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
          <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Respiratory Function</title>
        <description>Change in respiratory function after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
        <time_frame>12 weeks and 3 months</time_frame>
        <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Somatuline Depot SC</title>
            <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Respiratory Function</title>
          <description>Change in respiratory function after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
          <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life</title>
        <description>Change in Quality of Life after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
        <time_frame>3 months</time_frame>
        <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Somatuline Depot SC</title>
            <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life</title>
          <description>Change in Quality of Life after 12 weeks of Somatuline therapy and 3 months after endonasal endoscopic adenoma removal</description>
          <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Remission Status 1 Year After Surgery</title>
        <description>Remission status one year after surgery and time to achieve remission in patients who did not achieve remission after endonasal endoscopic surgery and who had resumption of Somatuline Depot therapy 3 months after surgery.</description>
        <time_frame>12 months post-op</time_frame>
        <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Somatuline Depot SC</title>
            <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Status 1 Year After Surgery</title>
          <description>Remission status one year after surgery and time to achieve remission in patients who did not achieve remission after endonasal endoscopic surgery and who had resumption of Somatuline Depot therapy 3 months after surgery.</description>
          <population>2 patients treated; data not analyzed because study terminated prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Somatuline Depot SC</title>
          <description>Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.&#xD;
lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>due to blood loss during surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, specify</sub_title>
                <description>ears feel full of water</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <description>anosmia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Kelly</name_or_title>
      <organization>JOHN WAYNE CANCER INSTITUTE</organization>
      <phone>310-582-7450</phone>
      <email>Daniel.Kelly2@providence.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

